In proof‐of‐concept preclinical studies involving genetically engineered and xenograft (human cell line and patient‐derived) KRAS mutant LAC models, the genetic and therapeutic targeting of ADAM17, the latter with a new class of specific ADAM17 prodomain inhibitor (Wong et al, 2016), markedly suppressed tumor growth. This evidence concerns the gene KRAS and neoplasm.